Learn about five serious mental health conditions that often necessitate inpatient treatment. Understanding these challenges ...
Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Compass Pathways (CMPS) to $15 from $23 and keeps a Buy rating on the ...
Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...
In South Florida, innovative ideas are being employed every day to deal with climate change threats. Start-up tech companies ...
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
A local psychiatrist is taking a unique approach to treating depression at his Saratoga County practice. Manuel Astruc, M.D. & Associates provides Transcranial Magnetic Stimulation Therapy. It's a non ...
Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.
Fintel reports that on February 27, 2025, Stifel initiated coverage of COMPASS Pathways plc - Depositary Receipt () (NasdaqGS ...